TY - JOUR
T1 - Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
AU - Forrat, Rémi
AU - Dayan, Gustavo H.
AU - DiazGranados, Carlos A.
AU - Bonaparte, Matthew
AU - Laot, Thelma
AU - Capeding, Maria Rosario
AU - Sanchez, Leilani
AU - Coronel, Diana Leticia
AU - Reynales, Humberto
AU - Chansinghakul, Danaya
AU - Hadinegoro, Sri Rezeki S.
AU - Perroud, Ana Paula
AU - Frago, Carina
AU - Zambrano, Betzana
AU - Machabert, Tifany
AU - Wu, Yukun
AU - Luedtke, Alexander
AU - Price, Brenda
AU - Vigne, Claire
AU - Haney, Owen
AU - Savarino, Stephen J.
AU - Bouckenooghe, Alain
AU - Noriega, Fernando
N1 - Publisher Copyright:
© The Author(s) 2021.
PY - 2021/9/15
Y1 - 2021/9/15
N2 - BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (
AB - BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (
KW - CYD-TDV
KW - dengue
KW - serostatus
KW - VCD
UR - http://www.scopus.com/inward/record.url?scp=85116958578&partnerID=8YFLogxK
U2 - 10.1093/cid/ciab288
DO - 10.1093/cid/ciab288
M3 - Article
C2 - 33822015
AN - SCOPUS:85116958578
VL - 73
SP - 1003
EP - 1012
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 6
ER -